Literature DB >> 32927932

Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Elifcan Aladağ Karakulak1, Haluk Demİroğlu1, Umit Yavuz Malkan2, Umit Akman1, Hakan Göker1, Yahya Büyükaşik1.   

Abstract

Background/aim: Graft-versus-host disease (GVHD) is a crucial complication leading to significant morbidity and mortality allogeneic hematopoietic stem cell transplantation which occurs in approximately half of the transplant recipients. Suppression of tumorigenicity 2 (ST2) and regenerating islet-derived 3-alpha(Reg3a) might be important biomarkers to predict acute GVHD. Materials and methods: In the present study, blood samples were collected from 17 patients with acute GVHD and 12 control patients after allogeneic stem cell transplantation. ST2 and Reg3a were measured in plasma samples compared in patients with acute GVHD and the controls.
Results: Median age of the study population was 42 years (range 19–49). When compared to controls, the mean ST2 levels was significant higher in acute GVHD (9794 ng/dL vs. 2646 ng/dL, P = 0.008). Mean Reg3a level did not show significant difference between control and acute GVHD group (8848 ng/dL vs. 5632 ng/dL, respectively, P = 0.190).
Conclusion: The ST2 level might be used as a significant biomarker for predicting acute GVHD. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  Suppression of tumorigenicity 2; regenerating isletderived 3-alpha; graft-versus-host disease; allogeneic hematopoietic stem cell transplantation

Year:  2021        PMID: 32927932      PMCID: PMC7991887          DOI: 10.3906/sag-2007-17

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  11 in total

Review 1.  Acute graft-vs-host disease: pathobiology and management.

Authors:  H Goker; I C Haznedaroglu; N J Chao
Journal:  Exp Hematol       Date:  2001-03       Impact factor: 3.084

2.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Authors:  Matthew J Hartwell; Umut Özbek; Ernst Holler; Anne S Renteria; Hannah Major-Monfried; Pavan Reddy; Mina Aziz; William J Hogan; Francis Ayuk; Yvonne A Efebera; Elizabeth O Hexner; Udomsak Bunworasate; Muna Qayed; Rainer Ordemann; Matthias Wölfl; Stephan Mielke; Attaphol Pawarode; Yi-Bin Chen; Steven Devine; Andrew C Harris; Madan Jagasia; Carrie L Kitko; Mark R Litzow; Nicolaus Kröger; Franco Locatelli; George Morales; Ryotaro Nakamura; Ran Reshef; Wolf Rösler; Daniela Weber; Kitsada Wudhikarn; Gregory A Yanik; John E Levine; James Lm Ferrara
Journal:  JCI Insight       Date:  2018-08-23

3.  Graft-versus-host disease treatment: predictors of survival.

Authors:  John E Levine; Brent Logan; Juan Wu; Amin M Alousi; Vincent Ho; Javier Bolaños-Meade; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-09       Impact factor: 5.742

4.  High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

Authors:  Doris M Ponce; Patrick Hilden; Christen Mumaw; Sean M Devlin; Marissa Lubin; Sergio Giralt; Jenna D Goldberg; Alan Hanash; Katharine Hsu; Robert Jenq; Miguel-Angel Perales; Craig Sauter; Marcel R M van den Brink; James W Young; Renier Brentjens; Nancy A Kernan; Susan E Prockop; Richard J O'Reilly; Andromachi Scaradavou; Sophie Paczesny; Juliet N Barker
Journal:  Blood       Date:  2014-11-06       Impact factor: 22.113

5.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Authors:  James L M Ferrara; Andrew C Harris; Joel K Greenson; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W J Choi; Elisabeth Huber; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Pavan Reddy; Alice Chin; Qing Zhang; Samir Hanash; Sophie Paczesny
Journal:  Blood       Date:  2011-10-06       Impact factor: 22.113

6.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

Review 7.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

Review 8.  Management of acute graft-versus-host disease.

Authors:  Andrea Bacigalupo
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

9.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

Authors:  Mark T Vander Lugt; Thomas M Braun; Samir Hanash; Jerome Ritz; Vincent T Ho; Joseph H Antin; Qing Zhang; Chee-Hong Wong; Hong Wang; Alice Chin; Aurélie Gomez; Andrew C Harris; John E Levine; Sung W Choi; Daniel Couriel; Pavan Reddy; James L M Ferrara; Sophie Paczesny
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

10.  Acute Graft-Versus-Host Disease: A Brief Review

Authors:  Elifcan Aladağ; Engin Kelkitli; Hakan Göker
Journal:  Turk J Haematol       Date:  2019-09-02       Impact factor: 1.831

View more
  1 in total

1.  Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Kinga Kwiecinska; Wojciech Strojny; Miroslaw Bik-Multanowski; Marcin Piechota; Walentyna Balwierz
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.